ELCC 2021 | Using clinical trials to drive treatment approaches in lung cancer

Andrew Robinson, MD, MSc, FRCPC, Queen’s University, Kingston, ON, discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous non-small cell lung cancer (NSCLC), highlighting data on pembrolizumab and chemotherapy from the KEYNOTE-407 trial (NCT02775435). This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.